General Information of This Drug (ID: DME321B)

Drug Name
VX-944   DME321B
Synonyms
AVN-944; AVN944; 297730-17-7; AVN 944; UNII-I3NPL1V48Q; I3NPL1V48Q; 501345-02-4; VX 944; SCHEMBL19784823; CHEMBL3349001; DTXSID80183921; EX-A778; AOB5557; ZINC3963015; AKOS027340045; CS-3427; NCGC00345803-01; NCGC00345803-05; HY-13560; AS-16899; SC-82478; (R)-1-cyanobutan-2-yl ((S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate; Carbamic acid, ((1S)-1-(3-((((3-methoxy-4-(5- oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1R)-1-(cyanomethyl)propyl ester; (2R)-1-cyanobutan-2-yl N-[(1S)-1-[3-({[3-metho
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
VX-944 + Panobinostat DCW2MZJ Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
VX-944 + Ruxolitinib DCGUGMV Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00493441) AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer. U.S. National Institutes of Health.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.